HR 8662 116th Congress House Health Advisory bodies Congressional oversight Drug safety, medical device, and laboratory regulation Drug therapy Government information and archives Health care coverage and access Health care quality Health information and medical records Health programs administration and funding Health promotion and preventive care Medical research Medical tests and diagnostic methods Neurological disorders Public contracts and procurement Research administration and funding Research and development

Accelerating Access to Critical Therapies for ALS Act

Introduced: October 23, 2020 See on congress.gov

Everywhere this bill has been 2 steps

Introduced

In committee

Reported out

Passed House

Passed Senate

To President

Became law

Oct 23, 2020

Referred to the House Committee on Energy and Commerce.

Oct 23, 2020

Introduced in House

Plain-English summary Congressional Research Service

Accelerating Access to Critical Therapies for ALS Act

This bill establishes grant programs to address neurodegenerative diseases, such as amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's disease), and contains other related provisions.

The Department of Health and Human Services (HHS) shall award grants to eligible entities to support research on and facilitate access to investigational drugs that diagnose or treat ALS. The Food and Drug Administration shall award grants to public and private entities to cover the costs of research and development of drugs that diagnose or treat ALS and other severely debilitating neurodegenerative diseases.

HHS shall also establish the Collaborative for Neurodegenerative Diseases, which shall support the development and regulatory approval of drugs that address ALS and other rare neurodegenerative diseases.

Accelerating Access to Critical Therapies for ALS Act

Social media images

For video overlays

Light mode